Rapid Dose Therapeutics Announces Research Results Published in Frontiers in Pharmacology Journal
September 12 2019 - 7:00AM
Rapid Dose Therapeutics Corp. (“RDT”)
(CSE: DOSE) announced today that the results of a
research study conducted by the University of Nevada, Las Vegas
(“UNLV”) was published in the high impact journal, Frontiers in
Pharmacology, on September 10, 2019.
RDT’s proprietary QuickStrip™ technology is an oral dispersible
thin film drug delivery system that rapidly delivers active
medicinal agents directly to the bloodstream via transfer through
the sublingual or buccal mucosa (mouth), bypassing metabolism of
the active agent in the gastrointestinal tract.
A bioanalytical study was conducted in collaboration with
researchers from UNLV to evaluate QuickStrip™ oral thin film
delivery, in mice, of caffeine for onset time, bioavailability, and
effects on the central nervous system as measured by
high-performance liquid chromatography and electroencephalogram
(“EEG”), compared to direct administration into the stomach
via the gavage method.
The study was led by UNLV neuroscientists, Dr. Rochelle Hines
and Dr. Dustin Hines, whose research programs are focused on the
study of neuropsychiatric disorders including developmental
epilepsies, autism, schizophrenia, depression sleep disorders, and
Alzheimer’s disease.
“Our work demonstrated that by using this technology, caffeine
was delivered into the bloodstream quickly and with twice the
bioavailability of traditional means,” said Dustin Hines, UNLV
neuroscientist and study co-author.
The study showed that QuickStrip™ delivery resulted in higher
serum levels of the active agent measured between one minute and 30
minutes following administration, and greater bioavailability
compared to gavage. EEG results demonstrated that QuickStrip™
delivery of caffeine is rapidly absorbed, permitting quick and
effective access to the central nervous system.
“We developed QuickStrip™ as a novel and versatile delivery
system with many applications, including nutraceuticals and
pharmaceuticals, among others. We are excited to announce the study
results from UNLV which concluded that, for caffeine, RDT’s
proprietary QuickStrip™ delivery method produced greater
bioavailability compared to gavage and speed of uptake
comparatively,” said Mark Upsdell, CEO of RDT. “RDT will
continue to expand our research programs to further strengthen our
unique delivery leadership position. We are committed to providing
consumers in the global medical and personal product markets
research-based validation that QuickStrip™ is a delivery system
that is Quick, Convenient, Precise and Discreet™,” added
Upsdell.
About Rapid Dose
TherapeuticsRapid Dose Therapeutics Corp. is a
publicly-traded Canadian life sciences company that provides
innovative, proprietary drug delivery technologies designed to
improve outcomes and quality of lives. RDT offers Quick,
Convenient, Precise and Discreet™ choices to consumers. RDT is
focused and committed to clinical research and product development
for the healthcare manufacturing industry, including the
nutraceutical and pharmaceutical industries, among others. RDT’s
service-based annuity contracts drive recurring revenue which
enables rapid expansion into emerging markets — generating value
for consumers and shareholders. Rapid Dose Therapeutics is
committed to continually create innovative solutions aimed at
multiple consumer segments and future market needs — including
humans, animals and plants.
For more information, visit: www.rapid-dose.comFor inquiries
please contact:Ian Fodie, CFO
Rapid Dose Therapeutics Corp.
ifodie@rapid-dose.com
Office (416) 477-1052
Ali Mahdavi, Managing Director Spinnaker Capital Markets
Inc.am@spinnakercmi.com Office (416) 962-3300
Social
MediaRapidDoseTherapeutics.linkedinRapidDoseTherapeutics.twitterRapidDoseTherapeutics.facebookQuickStrip.instagram
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS: Certain information in this
news release may contain forward-looking information within the
meaning of applicable securities laws. Any statements that are
contained in this news release that are not statements of
historical fact may be deemed to be forward- looking statements.
Forward looking statements are often identified by terms such as
“may”, “should”, “anticipate”, “expect”, “potential”, “believe”,
“intend” or the negative of these terms and similar expressions.
Statements containing forward-looking information, including,
without limitation, in respect of the delivery of products using
the QuickStrip™ product delivery method, express, as at the date of
this news release, the plans, estimates, forecasts, projections,
expectations or beliefs of RDT as to future events or results and
are believed to be reasonable based on information currently
available to them. Forward-looking statements necessarily involve
known and unknown risks, including, without limitation, risks
associated with general economic conditions; adverse industry
events; marketing costs; loss of markets; future legislative and
regulatory developments involving cannabis; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favourable terms; the
cannabis industry in Canada generally, income tax and regulatory
matters; the ability to implement its business strategies;
competition; currency and interest rate fluctuations and other
risks. Readers are cautioned that the foregoing list is not
exhaustive. There can be no assurance that statements of
forward-looking information, although considered reasonable by
management at the time of preparation, will prove to be accurate as
there can be no assurance that the plans, intentions or
expectations upon which they are based will occur. Actual results
and future events could differ materially from those anticipated in
such statements. Readers should not place undue reliance on
forward-looking information. Forward-looking statements contained
in this news release are expressly qualified by this cautionary
statement.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e563dcd5-ad0f-43fd-9fac-20349040af72
Rapid Dose Therapeutics (CSE:DOSE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rapid Dose Therapeutics (CSE:DOSE)
Historical Stock Chart
From Jul 2023 to Jul 2024